mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Versus mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced pMMR/MSS Colorectal Cancer: A Prospective, Multicenter, Randomized Phase III Study (BASKETIII)
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Sintilimab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms BASKET III
- 03 Feb 2025 New trial record